Marksans Pharma Limited (NSE:MARKSANS)

India flag India · Delayed Price · Currency is INR
245.85
+3.05 (1.26%)
Jun 25, 2025, 9:30 AM IST
51.06%
Market Cap 110.03B
Revenue (ttm) 26.23B
Net Income (ttm) 3.81B
Shares Out 453.16M
EPS (ttm) 8.40
PE Ratio 28.90
Forward PE 22.59
Dividend 0.80 (0.33%)
Ex-Dividend Date Sep 17, 2024
Volume 154,476
Average Volume 1,258,675
Open 243.50
Previous Close 242.80
Day's Range 241.80 - 246.00
52-Week Range 158.22 - 358.70
Beta 1.38
RSI 45.57
Earnings Date May 30, 2025

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin... [Read more]

Sector Healthcare
Founded 1992
Employees 1,141
Stock Exchange National Stock Exchange of India
Ticker Symbol MARKSANS
Full Company Profile

Financial Performance

In 2024, Marksans Pharma's revenue was 26.23 billion, an increase of 20.46% compared to the previous year's 21.77 billion. Earnings were 3.81 billion, an increase of 21.32%.

Financial Statements

News

Marksans Pharma’s UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution

Marksans Pharma Limited announced today that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution from the...

6 days ago - Business Upturn

Marksans Pharma shares jump 3% after large block deal worth Rs 257 crore

Shares of Marksans Pharma Ltd climbed 2.92% to ₹257.25 in early trade on Wednesday, June 11, following a significant block deal executed in Tuesday’s session. According to exchange data, around 1.02 c...

14 days ago - Business Upturn

Marksans Pharma Block Deal: Over 1 crore shares worth Rs 257 crore change hands at Rs 249.95 per share

Shares of Marksans Pharma Ltd. will be in focus on Wednesday, June 11, after a significant block deal took place during Tuesday’s trading session. As per exchange data, 1,02,73,443 shares of the compa...

14 days ago - Business Upturn

Marksans Pharma’s subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution

Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA...

26 days ago - Business Upturn

Marksans Pharma’s UK arm gets marketing approval for Sennosides 7.5 mg tablets

Shares of Marksans Pharma could remain in focus after the company announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization for Sennosides 7.5 mg tablets f...

5 weeks ago - Business Upturn

Marksans Pharma’s UK subsidiary Relonchem gets UKMHRA nod for Gabapentin oral solution

Marksans Pharma Limited announced on May 15 that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency...

5 weeks ago - Business Upturn

Marksans Pharma’s subsidiary receives one USFDA observation after cGMP inspection at New York facility

Marksans Pharma Limited has announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facilit...

2 months ago - Business Upturn

Marksans Pharma shares up nearly 4% as company secures Australian TGA approval for Goa facility

Shares of Marksans Pharma Limited surged nearly 4% after the company announced that its manufacturing facility at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, has received approval from t...

3 months ago - Business Upturn

Marksans Pharma’s Goa facility gets Australian TGA approval for Solid Dosage manufacturing

Marksans Pharma Limited has received approval from the Australian Therapeutic Goods Administration (TGA) for its state-of-the-art manufacturing facility in Verna, Goa. This approval allows the company...

3 months ago - Business Upturn

Marksans Pharma’s subsidiary Relonchem receives marketing authorization from UK MHRA for Baclofen 10 mg tablets

Marksans Pharma Limited has achieved a key milestone as its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Ag...

3 months ago - Business Upturn

Marksans Pharma’s subsidiary Relonchem gets UK approval for Ibuprofen and Paracetamol tablets

Marksans Pharma Limited has announced that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets in the U...

4 months ago - Business Upturn

Marksans Pharma shares jump 2% following USFDA approval for Loratadine Tablets USP 10 mg

Marksans Pharma Limited saw a 2% surge in its stock price after receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine...

7 months ago - Business Upturn

Marksans Pharma receives USFDA approval for Loratadine Tablets USP 10 mg

Marksans Pharma Limited has announced receiving final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg. This...

7 months ago - Business Upturn

Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and ...

Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansion

7 months ago - GuruFocus

Marksans Pharma shares jump over 3% on Q2 results

Marksans Pharma Ltd. has announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024, reflecting strong growth in both revenue and prof...

8 months ago - Business Upturn

Marksans Pharma Q2 FY25: Revenue up 20.84% YoY to Rs 641.92 crore, Net Profit up 16.56% YoY

Marksans Pharma Ltd. reported unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024. Q2 FY25 financial analysis for Marksans Pharma with figure...

8 months ago - Business Upturn

Marksans Pharma Q2 FY25 results: Stock surge over 3% ahead of result announcement

Marksans Pharma’s stock saw a significant uptick, jumping over 3% ahead of its Q2 FY25 results. The stock opened at ₹290.70, reaching a high of ₹299.20, and closing near its low of ₹290.65. With a 52-...

8 months ago - Business Upturn